Blade Therapeutics Initiates Additional Phase 1 Clinical Study of Cudetaxestat, a Non-Competitive Autotaxin Inhibitor in Clinical Development for Idiopathic Pulmonary Fibrosis
Blade Therapeutics Announces Publication of Preclinical Evidence Supporting Neuroprotective Effects of Proprietary Calpain Inhibitor in a Rare Inherited Neurodegenerative Disease